T cell receptor-like recognition of tumor in vivo by synthetic antibody fragment.
A major difficulty in treating cancer is the inability to differentiate between normal and tumor cells. The immune system differentiates tumor from normal cells by T cell receptor (TCR) binding of tumor-associated peptides bound to Major Histocompatibility Complex (pMHC) molecules. The peptides, der...
Guardado en:
Autores principales: | Keith R Miller, Akiko Koide, Brenda Leung, Jonathan Fitzsimmons, Bryan Yoder, Hong Yuan, Michael Jay, Sachdev S Sidhu, Shohei Koide, Edward J Collins |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/63f17489ca874bf196d8e8ddb9f027b5 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Targeted rescue of cancer-associated IDH1 mutant activity using an engineered synthetic antibody
por: Shahir S. Rizk, et al.
Publicado: (2017) -
Selective and noncovalent targeting of RAS mutants for inhibition and degradation
por: Kai Wen Teng, et al.
Publicado: (2021) -
The structural basis of promiscuity in small multidrug resistance transporters
por: Ali A. Kermani, et al.
Publicado: (2020) -
Recognition of Chiral Carboxylates by Synthetic Receptors
por: Patryk Niedbała, et al.
Publicado: (2021) -
Isolation and characterisation of a human-like antibody fragment (scFv) that inactivates VEEV in vitro and in vivo.
por: Torsten Rülker, et al.
Publicado: (2012)